Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: microRNA-186 in extracellular vesicles from bone marrow mesenchymal stem cells alleviates idiopathic pulmonary fibrosis via interaction with SOX4 and DKK1

Fig. 3

miR-186 in BMSC-EVs inhibits the fibroblast activation. a The expression of miR-186 in lung tissues of patients with IPF (n = 48) and control donors (n = 16) determined by RT-qPCR. b Expression of miR-186 in the EVs secreted by BMSCs from three hospitalized patients with femoral head necrosis determined by RT-qPCR. c The miR-186 expression in BMSCs and BMSC-EVs determined by RT-qPCR. In dk, fibroblasts LL29 were treated with PBS or EVs from BMSCs transfected with miR-186 inhibitor or inhibitor-NC. d The detection of miR-186 expression in the fibroblasts by RT-qPCR. e The proliferation of fibroblasts assessed by CCK8. f, g The migration and invasion of the fibroblasts evaluated by Transwell assay. h Cell cycle of fibroblasts analyzed by flow cytometry. i Apoptosis of fibroblasts evaluated by flow cytometry. j, k The mRNA (j) and protein (k) expression of myofibroblastic markers α-SMA and collagen I in the fibroblasts measured by RT-qPCR and western blot analysis. *p < 0.05 vs. the control donors, case#1, BMSCs or fibroblasts treated with PBS; #p < 0.05 vs. the fibroblasts treated with EVs from BMSCs transfected with inhibitor-NC. Differences between two groups were compared by unpaired t test, while differences among groups were determined by one-way ANOVA, followed by Tukey’s multiple comparisons post-test. Besides, the comparison of the data in each group at different time points was analyzed by two-way ANOVA. The experiment was repeated three times

Back to article page